NCT03963414 - A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 25, 2020

Primary Completion Date

December 15, 2021

Study Completion Date

December 15, 2021

Conditions

Small Cell Lung Carcinoma

Interventions

COMBINATION_PRODUCT

Durvalumab + Tremelimumab in combination with carboplatin and etoposide

1500mg of durvalumab plus 75mg of tremelimumab in combination with carboplatin and etoposide will be given every 3 weeks for Cycles 3 and 4. 1500mg of durvalumab plus 75mg of tremelimumab will be given every 3 weeks for Cycles 5 and 6.

COMBINATION_PRODUCT

Durvalumab in combination with carboplatin and etoposide

1500mg of durvalumab in combination with carboplatin and etoposide will be given every 3 weeks for Cycles 3 and 4.

Trial Locations (1)

68198

University of Nebraska Medical Center, Omaha